Shanghai Fosun Pharmaceutical (Group) (HKG:2196) said its unit's Botulinum Toxin Type A for Injection application for new drug registration was approved by China's National Medical Products Administration (NMPA), according to a Monday filing with the Hong Kong bourse.
The drug is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator or procerus muscle activity in adult patients.
The pharmaceutical company's stocks were down by nearly 1% at Tuesday's closing.
Price (HKD): $11.78, Change: $-0.060, Percent Change: -0.51%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments